Martin Welschof is currently CEO of BioInvent International.

“Martin will be an important contributor as we transition to a clinical stage company and further advance our precision T-cell therapies that have the potential to transform patient outcomes in a range of hard-to-treat solid tumour indications,” says Reagan Jarvis, Co-founder, and CEO, Anocca.

Martin Welschof

Martin Welschof holds a PhD in the field of recombinant antibody technology from the University of Bielefeld.

“Anocca’s unique approach and end-to-end capability from discovery to manufacturing puts it firmly at the forefront of establishing TCR-T therapy as a new modality for the treatment of cancer. The company has made impressive progress since its inception, and I look forward to working with the team as it pushes forward into the clinic,“ says Martin Welschof.

Photo: Nille Leander